June 21, 2024

Office of the Chief Accountant

Securities and Exchange Commission

100 F Street, N. E.

Washington, D.C. 20549

Ladies and Gentlemen:

We have read the comments made regarding us in Item 4.01 of Form 8-K of Eton Pharmaceuticals, Inc. dated June 14, 2024, and are in agreement with those statements.

/s/ KMJ Corbin & Company LLP

Irvine, California

Attachments

  • Original Link
  • Permalink

Disclaimer

Eton Pharmaceuticals Inc. published this content on 21 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 June 2024 20:18:33 UTC.